243 results
Page 2 of 13
8-K
EX-99.1
1v67uw0lmzqspfx9ihlt
11 Aug 22
Acasti Pharma Reports First Quarter 2023 Operational Results
7:05am
8-K
EX-99..1
pw4 tos8q3rt4qjljdub
21 Jun 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
8p41mxi0js4d9ni
18 May 22
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints
7:37am
8-K
EX-99.1
97l8x7z6leg0ou
25 Mar 22
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
7:36am
8-K
EX-99.1
qycb2h2eketniohgxx5
14 Feb 22
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
7:10am
8-K
EX-99.1
25cj o2gg1
2 Dec 21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
7:17am
8-K
EX-99.1
n67ww303 ru0mepqzyd1
15 Nov 21
Acasti Pharma Announces Annual Stock Option Grants
12:00am
8-K
EX-99.1
sgm0n
10 Nov 21
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022
7:09am
8-K
EX-99.1
2c8zc
22 Sep 21
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
8:30am
8-K
EX-99.2
c4kkg y7h
27 Aug 21
Completion of Acquisition or Disposition of Assets
8:47am
425
EX-99.1
xsi8e hj0rj5l5n19
12 Aug 21
Business combination disclosure
11:00am
8-K
EX-99.1
dad23rd5q ng
12 Aug 21
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
10:57am
8-K
EX-99.1
phiw6dk
23 Jul 21
Other Events
8:43am
425
EX-99.1
im4 71lvllxb
23 Jul 21
Business combination disclosure
8:41am
424B3
2v5ev pr6hw9jo1d6b
15 Jul 21
Prospectus supplement
4:45pm
S-4/A
3hfihz99d2kzgym
13 Jul 21
Registration of securities issued in business combination transactions (amended)
4:41pm